Open AccessAbstract CT245: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies
Author(s) -
Jing Yang,
Gary Means,
Almudena Tercero,
Kristi L. Manjarrez,
Jan Hillson,
Stanford L. Peng
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-ct245
Subject(s) - medicine , pharmacodynamics , oncology , clinical trial , pembrolizumab , pharmacokinetics , pharmacology , immunotherapy , cancer